Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iclaprim versus vancomycin for Gram-positive hospital-acquired pneumonia
2007-003109-28Phase 2Completed
- Sponsor
- Arpida Ltd
- Start
- Jul 2007
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Iclaprim and vancomycin in hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) and pneumonia (3 arms), sponsored by Arpida Ltd. Primary endpoint: Clinical cure rate at test of cure. Started Jul 2007; status: completed.
02
Drugs
Iclaprimvancomycin
03
Conditions
hospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)pneumonia
Beyond the preview
Go deeper on 2007-003109-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003109-28.